Designs for Clinical Trials
|
|
- Cecil Caldwell
- 6 years ago
- Views:
Transcription
1 Designs for Clinical Trials
2 Chapter 5 Reading Instructions 5.: Introduction 5.: Parallel Group Designs (read) 5.3: Cluster Randomized Designs (less important) 5.4: Crossover Designs (read+copies) 5.5: Titration Designs (read) 5.6: Enrichment Designs (less important) 5.7: Group Sequential Designs (read include.6) 5.8: Placebo-Challenging Designs (less important) 5.9: linded Reader Designs (less important) 5.: Discussion
3 Design issues
4 Design issues Research question Statistical optimality not enough! Use simulation models! Confounding Objective Control Statistics Design, Variables Ethics Variability Cost Feasibility
5 Parallel Group Designs R Test Control Control Yij = µ + ε i i =, K, n j j =, K,k ij Easy to implement ccepted Easy to analyse Good for acute conditions ε ij ( ), ~ N σ
6 Where does the varation go? Placebo Drug X 8 week blood pressure Y = Xβ + ε nything we can explain Unexplained
7 etween and within subject variation DP mmhg Placebo Drug X Female Male aseline 8 weeks
8 What can be done? Stratify: Randomize by baseline covariate and put the covariate in the model. More observations per subject: aseline More than obsservation per treatment Run in period: Ensure complience, diagnosis
9 Parallell group design with baseline Compare bloodpressure for three treatments, one test and two control. R Test Control Control aseline 8 weeks Model: Yijk = µ + { i=} τ j + ξk + ε Observation i =, ijk Treatment j =,,3 Treatment effect τ j Subject k =, K,n ( ξ iid, ) j Subject effect k N σ s Random error ε ijk iid N (, σ )
10 Change from baseline The variance of an 8 week value is Var ( Y ) ( ) jk = Var µ + { i=} τ j + ξk + εijk ( ξ + ε ) = Var( ξ ) + Var( ε )= = Var k ijk k ijk σ s +σ Change from baseline = Y Y = ε ( τ + ) Z jk jk jk jk j ε jk The variance of change from baseline is σ Usually σ < σ s σ < σ + σ s
11 aseline as covariate R Test Control Control aseline 8 weeks Model: Y ij Treatment effect aseline value Random error = µ + τ + βx + ε ε j τ j xi ijk iid i N ij (, σ ) Subject Treatment i =, K,n j j =,,3
12 Crossover studies ll subject gets more that one treatment Comparisons within subject R Wash out Sequence Sequence Period Period Within subject comparison Reduced sample size Good for cronic conditions Good for pharmaceutical studies
13 Model for a cross over study ξ Obs=Period+sequence+subject+treament+carryover+error Yijk γ i = effect of sequence i =, γ +γ = i( k ) = effect of subject k =, K, ni within sequence i iid N, π j = effect of period j =, π { } τ t = effect of treatment t, ε randomerror iid N, σ ijk = = + γ i + ξi( k ) µ + π + τ + δ λ + ε j t ( ) j r +π = ijk τ + τ = ( σ ) s
14 by Crossover design [ EY ]= ijk µ µ µ µ + π τ γ + π + τ + λ γ + γ + + π τ γ + π + τ + γ τ (( µ µ ) + ( µ µ )) (( π π + τ τ λ ) + ( π π + τ τ λ )) τ ( λ + λ ) = Effect of treatment and carry over can not be separated! =
15 Model: Sum to zero: Matrix formulation Yijk λ π τ Matrix formulation ( µ γ ) T π τ ( µ, µ, µ µ ) T β = µ =, = + γ i + ξi( k ) µ + π + τ + ε + λ = +π = +τ = µ = Xβ X j = t ijk
16 Matrix formulation Parameter estimate: ( X T X) X T Y ˆ β = σ ˆ = ( T Y Y ) T βx ˆ T ( ˆ β ) ( X T X) σˆ Cov = ( X T X) = Estimates independent and Var ( ˆ τ ) =.5 ˆ σ
17 lternatives to * Compare to Same model but with 3 periods and a carry over effect Yijk = + γ i + ξi( k ) ξ γ i π j µ + π + τ + δ λ + ε i( k ) = effect of subject k =, K, ni within sequence i iid N, = effect of sequence i =, = effect of period j =,,3 { } τ t = effect of treatment t, ε randomerror iid N, σ ijk = j t ( ) π γ j r + γ = +π = τ + τ = ijk ( σ ) s
18 Parameters of the, design Yijk = µ + γ i + ξi k + π j + τ t + ε [ ] ( ) ijk E Y ijk = µ ijk µ µ µ 3 µ µ µ 3 µ = µ + γ + π + τ µ = µ + γ + π + τ + λ µ 3 = µ + γ + π 3 + τ + λ µ µ + γ + π + = = µ + γ + π = µ + γ + π 3 τ µ + τ + λ µ 3 + τ + λ λ + λ = π + π + π 3 = τ +τ = λ λ = +
19 Matrix again = λ τ π π γ µ β X ( ) = X T X Effect of treatment and carry over can be estimated independently!
20 Other sequence 3 period designs 3 4 ( ) Var τˆ ( ) Var λˆ N/.5.. N/ 3 Corr ( ˆ τ, ˆ λ ) N/ 4
21 Comparing the, and the, designs ( ) Var ˆ τ =.5 ˆ σ ( ) ˆ ˆ Var τ =.9σ Can t include carry over Carry over estimable treatments per subject 3 treatments per subject Shorter duration Longer duration Excercise: Find the best treatment 4 period design
22 More than treatments Tool of the trade: Define the model ( ) X T X C C C C C C D C D C C D C D Investigate C C C C C Watch out for drop outs!
23 Titration Designs Increasing dose panels (Phase I): SD (Single scending Dose) MD (Multiple scending Dose) Primary Objective: Establish Safety and Tolerability Estimate Pharmaco Kinetic (PK) profile Increasing dose panelse (Phase II): Dose - response
24 VERY careful with first group! Titration Designs (SD, MD) Dose: Z mg X on drug Y on Placebo Dose: Z mg X on drug Y on Placebo Dose: Z k mg X on drug Y on Placebo Stop if any signs of safety issues
25 Titration Designs Which dose levels? Start dose based on exposure in animal models. Stop dose based on toxdata from animal models. Doses often equidistant on log scale. Which subject? Healty volunteers Young Male How many subjects? Rarely any formal power calculation. Often on placebo and 6-8 on drug.
26 Titration Designs Not mandatory to have new subject for each group. X mg X mg X 3 mg X 4 mg X 5 mg X Y mg Gr. Gr. Gr. Gr. Gr. 3 Gr Slighty larger groups to have sufficiently many exposed. Dose in fourth group depends on results so far. Possible to estimate within subject variation.
27 Factorial design Evaluation of a fixed combination of drug and drug placebo placebo active placebo P placebo active active active The U.S. FD s policy ( CFR 3.5) regarding the use of a fixed-dose combination The agency requires: Each component must make a contribution to the claimed effect of the combination. Implication: t specific component doses, the combination must be superior to its components at the same respective doses
28 Factorial design Usually the fixed-dose of either drug under study has been approved for an indication for treating a disease. Nonetheless, it is desirable to include placebo (P) to examine the sensitivity of either drug give alone at that fixed-dose (comparison of with P may be necessary in some situations). ssume that the same efficacy variable is used for studying both drugs (using different endpoints can be considered and needs more thoughts).
29 Factorial design Sample mean Y i N( µ i, σ/n ), i =,, n = sample size per treatment group (balanced design is assumed for simplicity). H: µ µ or µ µ H: µ > µ and µ > µ j=, n Y Yj T j = ; j, : ˆ = σ Min test and critical region: min ( T T ) C :, : >
30 Group sequential designs large study is a a huge investment, $, ethics What if the drug doesn t work or is much better than expected? Could we take an early look at data and stop the study is it look good (or too bad)?
31 Repeated significance test Let: ( ~ N, σ ) Y Test: H : µ = µ ij Test statistic: µ j ˆ ˆ mk µ µ = ˆµ = σ mk mk i= Z mk j Y ij For k =, KK If Z k Cα Stop, reject otherwise Continue to group k + If H Z k Cα Stop, reject H otherwise stop accept H
32 True type I error rate Repeat testing until H rejected Tests Critical value P(type I error)
33 Pocock s test Suppose we want to test the null hypothesis 5 times using the same critical value each time and keep the overall significance level at 5% k K If Z C ( α K ) For =, K fter group K Choose C p ( α, K ) k p, Stop, reject otherwise Continue to group k + Stop, reject H If Z C ( α K ) Such that k p, otherwise stop accept H H P( Reject H at any analysis k = K K) = α
34 Pocock s test Tests Critical value P(type I error) ll tests has the same nominal significance level group sequential test with 5 interrim tests has level ( (.43) ). 58 α' = φ =
35 Pocock s test Z k Reject H.43 ccept H stage k -.43 Reject H
36 O rian & Flemmings test Increasing nominal significance levels k K If Z C ( α, K ) K k For =, K fter group K : Choose C p ( α, K ) : k p / Stop, reject otherwise Continue to group k + If Z C ( α K ) k p, Stop, reject H otherwise stop accept H Such that P( Reject H at any analysis k = K K) = α H
37 O rian & Flemmings test Critical values and nominal significance levels for a O rian Flemming test with 5 interrim tests. Test (k) C (K,α) C (K,α)*Sqrt(K/k) α Rather close to 5%
38 O rian & Flemmings test Z k Stage K
39 Comparing Pocock and O rian Flemming O rian Flemming Pocock Test (k) C (K,a)*Sqrt(K/k) α C P (K,a) α
40 Comparing Pocock and O rian Flemming 6 4 Zk Stage k
41 Group Sequential Designs Pros: Efficiency Gain (Decreasing marginal benefit) Establish efficacy earlier Detect safety problems earlier Cons: Smaller safety data base Complex to run Need to live up to stopping rules!
42 Selection of a design The design of a clinical study is influenced by: Number of treatments to be compared Characteristics of the treatment Characteristics of the disease/condition Study objectives Inter and intra subject variability Duration of the study Drop out rates
43 ackup ack up: Var ( Y ) ( ) ( ) Y = Var Y + Var Y ( ) ( σ + σ + σ + σ ) = s s n n
Statistical tables are attached Two Hours UNIVERSITY OF MANCHESTER. May 2007 Final Draft
Statistical tables are attached wo Hours UNIVERSIY OF MNHESER Ma 7 Final Draft Medical Statistics M377 Electronic calculators ma be used provided that the cannot store tet nswer LL si questions in SEION
More informationCHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity
CHL 5225H Advanced Statistical Methods for Clinical Trials: Multiplicity Prof. Kevin E. Thorpe Dept. of Public Health Sciences University of Toronto Objectives 1. Be able to distinguish among the various
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Cross-over Designs #: DESIGNING CLINICAL RESEARCH The subtraction of measurements from the same subject will mostly cancel or minimize effects
More informationCHL 5225 H Crossover Trials. CHL 5225 H Crossover Trials
CHL 55 H Crossover Trials The Two-sequence, Two-Treatment, Two-period Crossover Trial Definition A trial in which patients are randomly allocated to one of two sequences of treatments (either 1 then, or
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 10 Class Summary Last time... We began our discussion of adaptive clinical trials Specifically,
More informationGroup sequential designs with negative binomial data
Group sequential designs with negative binomial data Ekkehard Glimm 1 Tobias Mütze 2,3 1 Statistical Methodology, Novartis, Basel, Switzerland 2 Department of Medical Statistics, University Medical Center
More informationST4241 Design and Analysis of Clinical Trials Lecture 4: 2 2 factorial experiments, a special cases of parallel groups study
ST4241 Design and Analysis of Clinical Trials Lecture 4: 2 2 factorial experiments, a special cases of parallel groups study Chen Zehua Department of Statistics & Applied Probability 8:00-10:00 am, Tuesday,
More informationUNIVERSITY OF TORONTO Faculty of Arts and Science
UNIVERSITY OF TORONTO Faculty of Arts and Science December 2013 Final Examination STA442H1F/2101HF Methods of Applied Statistics Jerry Brunner Duration - 3 hours Aids: Calculator Model(s): Any calculator
More informationBIOS 2083: Linear Models
BIOS 2083: Linear Models Abdus S Wahed September 2, 2009 Chapter 0 2 Chapter 1 Introduction to linear models 1.1 Linear Models: Definition and Examples Example 1.1.1. Estimating the mean of a N(μ, σ 2
More informationChapter 12. Analysis of variance
Serik Sagitov, Chalmers and GU, January 9, 016 Chapter 1. Analysis of variance Chapter 11: I = samples independent samples paired samples Chapter 1: I 3 samples of equal size J one-way layout two-way layout
More informationSTAT Final Practice Problems
STAT 48 -- Final Practice Problems.Out of 5 women who had uterine cancer, 0 claimed to have used estrogens. Out of 30 women without uterine cancer 5 claimed to have used estrogens. Exposure Outcome (Cancer)
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 5 Course Summary So far, we have discussed Group sequential procedures for two-sided tests Group
More informationAdaptive Designs: Why, How and When?
Adaptive Designs: Why, How and When? Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj ISBS Conference Shanghai, July 2008 1 Adaptive designs:
More informationAnalysis of Longitudinal Data. Patrick J. Heagerty PhD Department of Biostatistics University of Washington
Analsis of Longitudinal Data Patrick J. Heagert PhD Department of Biostatistics Universit of Washington 1 Auckland 2008 Session Three Outline Role of correlation Impact proper standard errors Used to weight
More informationGroup sequential designs for Clinical Trials with multiple treatment arms
Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Cologne, June 26, 2015 This project has received funding from the European Union s Seventh Framework
More information2 >1. That is, a parallel study design will require
Cross Over Design Cross over design is commonly used in various type of research for its unique feature of accounting for within subject variability. For studies with short length of treatment time, illness
More informationSample Size and Power I: Binary Outcomes. James Ware, PhD Harvard School of Public Health Boston, MA
Sample Size and Power I: Binary Outcomes James Ware, PhD Harvard School of Public Health Boston, MA Sample Size and Power Principles: Sample size calculations are an essential part of study design Consider
More informationPSI Journal Club March 10 th, 2016
PSI Journal Club March 1 th, 1 The analysis of incontinence episodes and other count data in patients with Overactive Bladder (OAB) by Poisson and negative binomial regression Martina R, Kay R, van Maanen
More informationMultiple Testing in Group Sequential Clinical Trials
Multiple Testing in Group Sequential Clinical Trials Tian Zhao Supervisor: Michael Baron Department of Mathematical Sciences University of Texas at Dallas txz122@utdallas.edu 7/2/213 1 Sequential statistics
More informationSample Size and Power Considerations for Longitudinal Studies
Sample Size and Power Considerations for Longitudinal Studies Outline Quantities required to determine the sample size in longitudinal studies Review of type I error, type II error, and power For continuous
More informationType I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim
Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim Frank Bretz Statistical Methodology, Novartis Joint work with Martin Posch (Medical University
More informationTESTS FOR EQUIVALENCE BASED ON ODDS RATIO FOR MATCHED-PAIR DESIGN
Journal of Biopharmaceutical Statistics, 15: 889 901, 2005 Copyright Taylor & Francis, Inc. ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543400500265561 TESTS FOR EQUIVALENCE BASED ON ODDS RATIO
More informationMATH Notebook 3 Spring 2018
MATH448001 Notebook 3 Spring 2018 prepared by Professor Jenny Baglivo c Copyright 2010 2018 by Jenny A. Baglivo. All Rights Reserved. 3 MATH448001 Notebook 3 3 3.1 One Way Layout........................................
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH The First Step: SAMPLE SIZE DETERMINATION THE ULTIMATE GOAL The most important, ultimate step of any of clinical research is to do draw inferences;
More informationAnalysis of Variance and Design of Experiments-II
Analsis of Variance and Design of Experiments-II MODULE VII LECTURE - 3 CROSS-OVER DESIGNS Dr. Shalabh Department of Mathematics & Statistics Indian Institute of Technolog Kanpur Analsis of variance Now
More informationRerandomization to Balance Covariates
Rerandomization to Balance Covariates Kari Lock Morgan Department of Statistics Penn State University Joint work with Don Rubin University of Minnesota Biostatistics 4/27/16 The Gold Standard Randomized
More informationDrawing Inferences from Statistics Based on Multiyear Asset Returns
Drawing Inferences from Statistics Based on Multiyear Asset Returns Matthew Richardson ames H. Stock FE 1989 1 Motivation Fama and French (1988, Poterba and Summer (1988 document significant negative correlations
More information6 Sample Size Calculations
6 Sample Size Calculations A major responsibility of a statistician: sample size calculation. Hypothesis Testing: compare treatment 1 (new treatment) to treatment 2 (standard treatment); Assume continuous
More informationOptimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping
: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj InSPiRe Conference on Methodology
More informationWelcome! Webinar Biostatistics: sample size & power. Thursday, April 26, 12:30 1:30 pm (NDT)
. Welcome! Webinar Biostatistics: sample size & power Thursday, April 26, 12:30 1:30 pm (NDT) Get started now: Please check if your speakers are working and mute your audio. Please use the chat box to
More informationSuperchain Procedures in Clinical Trials. George Kordzakhia FDA, CDER, Office of Biostatistics Alex Dmitrienko Quintiles Innovation
August 01, 2012 Disclaimer: This presentation reflects the views of the author and should not be construed to represent the views or policies of the U.S. Food and Drug Administration Introduction We describe
More informationexp{ (x i) 2 i=1 n i=1 (x i a) 2 (x i ) 2 = exp{ i=1 n i=1 n 2ax i a 2 i=1
4 Hypothesis testing 4. Simple hypotheses A computer tries to distinguish between two sources of signals. Both sources emit independent signals with normally distributed intensity, the signals of the first
More information8/04/2011. last lecture: correlation and regression next lecture: standard MR & hierarchical MR (MR = multiple regression)
psyc3010 lecture 7 analysis of covariance (ANCOVA) last lecture: correlation and regression next lecture: standard MR & hierarchical MR (MR = multiple regression) 1 announcements quiz 2 correlation and
More informationUse of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children
Use of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children Lisa Hampson, Franz Koenig and Martin Posch Department of Mathematics
More informationPower assessment in group sequential design with multiple biomarker subgroups for multiplicity problem
Power assessment in group sequential design with multiple biomarker subgroups for multiplicity problem Lei Yang, Ph.D. Statistical Scientist, Roche (China) Holding Ltd. Aug 30 th 2018, Shanghai Jiao Tong
More informationUsing SAS Proc Power to Perform Model-based Power Analysis for Clinical Pharmacology Studies Peng Sun, Merck & Co., Inc.
PharmaSUG00 - Paper SP05 Using SAS Proc Power to Perform Model-based Power Analysis for Clinical Pharmacology Studies Peng Sun, Merck & Co., Inc., North Wales, PA ABSRAC In this paper, we demonstrate that
More informationSTAT 525 Fall Final exam. Tuesday December 14, 2010
STAT 525 Fall 2010 Final exam Tuesday December 14, 2010 Time: 2 hours Name (please print): Show all your work and calculations. Partial credit will be given for work that is partially correct. Points will
More informationGroup Sequential Designs: Theory, Computation and Optimisation
Group Sequential Designs: Theory, Computation and Optimisation Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj 8th International Conference
More informationLecture Outline. Biost 518 Applied Biostatistics II. Choice of Model for Analysis. Choice of Model. Choice of Model. Lecture 10: Multiple Regression:
Biost 518 Applied Biostatistics II Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington Lecture utline Choice of Model Alternative Models Effect of data driven selection of
More informationLecture 23. November 15, Department of Biostatistics Johns Hopkins Bloomberg School of Public Health Johns Hopkins University.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSTA Module 10 Comparing Two Proportions
STA 2023 Module 10 Comparing Two Proportions Learning Objectives Upon completing this module, you should be able to: 1. Perform large-sample inferences (hypothesis test and confidence intervals) to compare
More informationBIOS 2083 Linear Models c Abdus S. Wahed
Chapter 5 206 Chapter 6 General Linear Model: Statistical Inference 6.1 Introduction So far we have discussed formulation of linear models (Chapter 1), estimability of parameters in a linear model (Chapter
More informationROI ANALYSIS OF PHARMAFMRI DATA:
ROI ANALYSIS OF PHARMAFMRI DATA: AN ADAPTIVE APPROACH FOR GLOBAL TESTING Giorgos Minas, John A.D. Aston, Thomas E. Nichols and Nigel Stallard Department of Statistics and Warwick Centre of Analytical Sciences,
More informationGeneralizing the MCPMod methodology beyond normal, independent data
Generalizing the MCPMod methodology beyond normal, independent data José Pinheiro Joint work with Frank Bretz and Björn Bornkamp Novartis AG Trends and Innovations in Clinical Trial Statistics Conference
More informationSTAT 135 Lab 10 Two-Way ANOVA, Randomized Block Design and Friedman s Test
STAT 135 Lab 10 Two-Way ANOVA, Randomized Block Design and Friedman s Test Rebecca Barter April 13, 2015 Let s now imagine a dataset for which our response variable, Y, may be influenced by two factors,
More informationA Gate-keeping Approach for Selecting Adaptive Interventions under General SMART Designs
1 / 32 A Gate-keeping Approach for Selecting Adaptive Interventions under General SMART Designs Tony Zhong, DrPH Icahn School of Medicine at Mount Sinai (Feb 20, 2019) Workshop on Design of mhealth Intervention
More informationThe Random Effects Model Introduction
The Random Effects Model Introduction Sometimes, treatments included in experiment are randomly chosen from set of all possible treatments. Conclusions from such experiment can then be generalized to other
More informationCase Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial
Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial William R. Gillespie Pharsight Corporation Cary, North Carolina, USA PAGE 2003 Verona,
More informationThe SEQDESIGN Procedure
SAS/STAT 9.2 User s Guide, Second Edition The SEQDESIGN Procedure (Book Excerpt) This document is an individual chapter from the SAS/STAT 9.2 User s Guide, Second Edition. The correct bibliographic citation
More informationADAPTIVE EXPERIMENTAL DESIGNS. Maciej Patan and Barbara Bogacka. University of Zielona Góra, Poland and Queen Mary, University of London
ADAPTIVE EXPERIMENTAL DESIGNS FOR SIMULTANEOUS PK AND DOSE-SELECTION STUDIES IN PHASE I CLINICAL TRIALS Maciej Patan and Barbara Bogacka University of Zielona Góra, Poland and Queen Mary, University of
More informationBios 6649: Clinical Trials - Statistical Design and Monitoring
Bios 6649: Clinical Trials - Statistical Design and Monitoring Spring Semester 2015 John M. Kittelson Department of Biostatistics & Informatics Colorado School of Public Health University of Colorado Denver
More informationAccurate Maximum Likelihood Estimation for Parametric Population Analysis. Bob Leary UCSD/SDSC and LAPK, USC School of Medicine
Accurate Maximum Likelihood Estimation for Parametric Population Analysis Bob Leary UCSD/SDSC and LAPK, USC School of Medicine Why use parametric maximum likelihood estimators? Consistency: θˆ θ as N ML
More informationSample Size Determination
Sample Size Determination 018 The number of subjects in a clinical study should always be large enough to provide a reliable answer to the question(s addressed. The sample size is usually determined by
More informationComparing Adaptive Designs and the. Classical Group Sequential Approach. to Clinical Trial Design
Comparing Adaptive Designs and the Classical Group Sequential Approach to Clinical Trial Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationBIOL 51A - Biostatistics 1 1. Lecture 1: Intro to Biostatistics. Smoking: hazardous? FEV (l) Smoke
BIOL 51A - Biostatistics 1 1 Lecture 1: Intro to Biostatistics Smoking: hazardous? FEV (l) 1 2 3 4 5 No Yes Smoke BIOL 51A - Biostatistics 1 2 Box Plot a.k.a box-and-whisker diagram or candlestick chart
More informationInterim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping
Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming and Optimal Stopping Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj
More informationwith the usual assumptions about the error term. The two values of X 1 X 2 0 1
Sample questions 1. A researcher is investigating the effects of two factors, X 1 and X 2, each at 2 levels, on a response variable Y. A balanced two-factor factorial design is used with 1 replicate. The
More informationThe t-distribution. Patrick Breheny. October 13. z tests The χ 2 -distribution The t-distribution Summary
Patrick Breheny October 13 Patrick Breheny Biostatistical Methods I (BIOS 5710) 1/25 Introduction Introduction What s wrong with z-tests? So far we ve (thoroughly!) discussed how to carry out hypothesis
More informationCTP-656 Tablet Confirmed Superiority Of Pharmacokinetic Profile Relative To Kalydeco in Phase I Clinical Studies
Tablet Confirmed Superiority Of Pharmacokinetic Profile Relative To Kalydeco in Phase I Clinical Studies 39 th European Cystic Fibrosis Conference 8-11 June 2016, Basel, Switzerland 2014 Concert Pharmaceuticals,
More informationStatistics & Data Sciences: First Year Prelim Exam May 2018
Statistics & Data Sciences: First Year Prelim Exam May 2018 Instructions: 1. Do not turn this page until instructed to do so. 2. Start each new question on a new sheet of paper. 3. This is a closed book
More informationSubgroup analysis using regression modeling multiple regression. Aeilko H Zwinderman
Subgroup analysis using regression modeling multiple regression Aeilko H Zwinderman who has unusual large response? Is such occurrence associated with subgroups of patients? such question is hypothesis-generating:
More informationStat 579: Generalized Linear Models and Extensions
Stat 579: Generalized Linear Models and Extensions Linear Mixed Models for Longitudinal Data Yan Lu April, 2018, week 12 1 / 34 Correlated data multivariate observations clustered data repeated measurement
More informationAnalysis of Variance
Analysis of Variance Blood coagulation time T avg A 62 60 63 59 61 B 63 67 71 64 65 66 66 C 68 66 71 67 68 68 68 D 56 62 60 61 63 64 63 59 61 64 Blood coagulation time A B C D Combined 56 57 58 59 60 61
More informationGroup Sequential Tests for Delayed Responses. Christopher Jennison. Lisa Hampson. Workshop on Special Topics on Sequential Methodology
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Lisa Hampson Department of Mathematics and Statistics,
More informationIntroduction to Crossover Trials
Introduction to Crossover Trials Stat 6500 Tutorial Project Isaac Blackhurst A crossover trial is a type of randomized control trial. It has advantages over other designed experiments because, under certain
More informationPractical issues related to the use of biomarkers in a seamless Phase II/III design
Practical issues related to the use of biomarkers in a seamless Phase II/III design Tomasz Burzykowski International Drug Development Institute Louvain-la-Neuve, Belgium tomasz.burzykowski@iddi.be www.iddi.com
More informationGroup sequential designs for negative binomial outcomes
Group sequential designs for negative binomial outcomes Tobias Mütze a, Ekkehard Glimm b,c, Heinz Schmidli b, and Tim Friede a,d a Department of Medical Statistics, University Medical Center Göttingen,
More informationWhat is Experimental Design?
One Factor ANOVA What is Experimental Design? A designed experiment is a test in which purposeful changes are made to the input variables (x) so that we may observe and identify the reasons for change
More informationWhen Should We Use Linear Fixed Effects Regression Models for Causal Inference with Longitudinal Data?
When Should We Use Linear Fixed Effects Regression Models for Causal Inference with Longitudinal Data? Kosuke Imai Department of Politics Center for Statistics and Machine Learning Princeton University
More informationAccounting for Correlation in the Analysis of Randomized Controlled Trials with Multiple Layers of Clustering
Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Spring 2016 Accounting for Correlation in the Analysis of Randomized Controlled Trials with Multiple Layers of Clustering
More informationSleep data, two drugs Ch13.xls
Model Based Statistics in Biology. Part IV. The General Linear Mixed Model.. Chapter 13.3 Fixed*Random Effects (Paired t-test) ReCap. Part I (Chapters 1,2,3,4), Part II (Ch 5, 6, 7) ReCap Part III (Ch
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 7 Course Summary To this point, we have discussed group sequential testing focusing on Maintaining
More informationGeneralizing the MCPMod methodology beyond normal, independent data
Generalizing the MCPMod methodology beyond normal, independent data José Pinheiro Joint work with Frank Bretz and Björn Bornkamp Novartis AG ASA NJ Chapter 35 th Annual Spring Symposium June 06, 2014 Outline
More informationEstimation of AUC from 0 to Infinity in Serial Sacrifice Designs
Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs Martin J. Wolfsegger Department of Biostatistics, Baxter AG, Vienna, Austria Thomas Jaki Department of Statistics, University of South Carolina,
More informationFactorial designs. Experiments
Chapter 5: Factorial designs Petter Mostad mostad@chalmers.se Experiments Actively making changes and observing the result, to find causal relationships. Many types of experimental plans Measuring response
More informationDESAIN EKSPERIMEN BLOCKING FACTORS. Semester Genap 2017/2018 Jurusan Teknik Industri Universitas Brawijaya
DESAIN EKSPERIMEN BLOCKING FACTORS Semester Genap Jurusan Teknik Industri Universitas Brawijaya Outline The Randomized Complete Block Design The Latin Square Design The Graeco-Latin Square Design Balanced
More informationGroup-Sequential Tests for One Proportion in a Fleming Design
Chapter 126 Group-Sequential Tests for One Proportion in a Fleming Design Introduction This procedure computes power and sample size for the single-arm group-sequential (multiple-stage) designs of Fleming
More informationApproximate analysis of covariance in trials in rare diseases, in particular rare cancers
Approximate analysis of covariance in trials in rare diseases, in particular rare cancers Stephen Senn (c) Stephen Senn 1 Acknowledgements This work is partly supported by the European Union s 7th Framework
More informationFactorial Treatment Structure: Part I. Lukas Meier, Seminar für Statistik
Factorial Treatment Structure: Part I Lukas Meier, Seminar für Statistik Factorial Treatment Structure So far (in CRD), the treatments had no structure. So called factorial treatment structure exists if
More informationMasters Comprehensive Examination Department of Statistics, University of Florida
Masters Comprehensive Examination Department of Statistics, University of Florida May 6, 003, 8:00 am - :00 noon Instructions: You have four hours to answer questions in this examination You must show
More informationMultiple Linear Regression
Multiple Linear Regression Simple linear regression tries to fit a simple line between two variables Y and X. If X is linearly related to Y this explains some of the variability in Y. In most cases, there
More informationRANDOMIZATIONN METHODS THAT
RANDOMIZATIONN METHODS THAT DEPEND ON THE COVARIATES WORK BY ALESSANDRO BALDI ANTOGNINI MAROUSSA ZAGORAIOU ALESSANDRA G GIOVAGNOLI (*) 1 DEPARTMENT OF STATISTICAL SCIENCES UNIVERSITY OF BOLOGNA, ITALY
More informationSTAC51: Categorical data Analysis
STAC51: Categorical data Analysis Mahinda Samarakoon January 26, 2016 Mahinda Samarakoon STAC51: Categorical data Analysis 1 / 32 Table of contents Contingency Tables 1 Contingency Tables Mahinda Samarakoon
More informationEconometrics of Panel Data
Econometrics of Panel Data Jakub Mućk Meeting # 2 Jakub Mućk Econometrics of Panel Data Meeting # 2 1 / 26 Outline 1 Fixed effects model The Least Squares Dummy Variable Estimator The Fixed Effect (Within
More informationDe-mystifying random effects models
De-mystifying random effects models Peter J Diggle Lecture 4, Leahurst, October 2012 Linear regression input variable x factor, covariate, explanatory variable,... output variable y response, end-point,
More informationDr. Shalabh Department of Mathematics and Statistics Indian Institute of Technology Kanpur
Analysis of Variance and Design of Experiments-I MODULE IV LECTURE - 3 EXPERIMENTAL DESIGNS AND THEIR ANALYSIS Dr. Shalabh Department of Mathematics and Statistics Indian Institute of Technology Kanpur
More informationDr. Shalabh Department of Mathematics and Statistics Indian Institute of Technology Kanpur
Analysis of Variance and Design of Experiment-I MODULE IX LECTURE - 38 EXERCISES Dr. Shalabh Department of Mathematics and Statistics Indian Institute of Technology Kanpur Example (Completely randomized
More information3. (a) (8 points) There is more than one way to correctly express the null hypothesis in matrix form. One way to state the null hypothesis is
Stat 501 Solutions and Comments on Exam 1 Spring 005-4 0-4 1. (a) (5 points) Y ~ N, -1-4 34 (b) (5 points) X (X,X ) = (5,8) ~ N ( 11.5, 0.9375 ) 3 1 (c) (10 points, for each part) (i), (ii), and (v) are
More informationEstimating the Mean Response of Treatment Duration Regimes in an Observational Study. Anastasios A. Tsiatis.
Estimating the Mean Response of Treatment Duration Regimes in an Observational Study Anastasios A. Tsiatis http://www.stat.ncsu.edu/ tsiatis/ Introduction to Dynamic Treatment Regimes 1 Outline Description
More informationStatistical Inference
Statistical Inference Jean Daunizeau Wellcome rust Centre for Neuroimaging University College London SPM Course Edinburgh, April 2010 Image time-series Spatial filter Design matrix Statistical Parametric
More informationDesign of Experiments. Factorial experiments require a lot of resources
Design of Experiments Factorial experiments require a lot of resources Sometimes real-world practical considerations require us to design experiments in specialized ways. The design of an experiment is
More informationReview 6. n 1 = 85 n 2 = 75 x 1 = x 2 = s 1 = 38.7 s 2 = 39.2
Review 6 Use the traditional method to test the given hypothesis. Assume that the samples are independent and that they have been randomly selected ) A researcher finds that of,000 people who said that
More informationAccounting for Baseline Observations in Randomized Clinical Trials
Accounting for Baseline Observations in Randomized Clinical Trials Scott S Emerson, MD, PhD Department of Biostatistics, University of Washington, Seattle, WA 9895, USA October 6, 0 Abstract In clinical
More informationTesting for bioequivalence of highly variable drugs from TR-RT crossover designs with heterogeneous residual variances
Testing for bioequivalence of highly variable drugs from T-T crossover designs with heterogeneous residual variances Christopher I. Vahl, PhD Department of Statistics Kansas State University Qing Kang,
More informationPerson-Time Data. Incidence. Cumulative Incidence: Example. Cumulative Incidence. Person-Time Data. Person-Time Data
Person-Time Data CF Jeff Lin, MD., PhD. Incidence 1. Cumulative incidence (incidence proportion) 2. Incidence density (incidence rate) December 14, 2005 c Jeff Lin, MD., PhD. c Jeff Lin, MD., PhD. Person-Time
More informationComparison of Different Methods of Sample Size Re-estimation for Therapeutic Equivalence (TE) Studies Protecting the Overall Type 1 Error
Comparison of Different Methods of Sample Size Re-estimation for Therapeutic Equivalence (TE) Studies Protecting the Overall Type 1 Error by Diane Potvin Outline 1. Therapeutic Equivalence Designs 2. Objectives
More informationA Bayesian Nonparametric Approach to Monotone Missing Data in Longitudinal Studies with Informative Missingness
A Bayesian Nonparametric Approach to Monotone Missing Data in Longitudinal Studies with Informative Missingness A. Linero and M. Daniels UF, UT-Austin SRC 2014, Galveston, TX 1 Background 2 Working model
More informationECON Introductory Econometrics. Lecture 5: OLS with One Regressor: Hypothesis Tests
ECON4150 - Introductory Econometrics Lecture 5: OLS with One Regressor: Hypothesis Tests Monique de Haan (moniqued@econ.uio.no) Stock and Watson Chapter 5 Lecture outline 2 Testing Hypotheses about one
More informationPubh 8482: Sequential Analysis
Pubh 8482: Sequential Analysis Joseph S. Koopmeiners Division of Biostatistics University of Minnesota Week 12 Review So far... We have discussed the role of phase III clinical trials in drug development
More informationROI analysis of pharmafmri data: an adaptive approach for global testing
ROI analysis of pharmafmri data: an adaptive approach for global testing Giorgos Minas, John A.D. Aston, Thomas E. Nichols and Nigel Stallard Abstract Pharmacological fmri (pharmafmri) is a new highly
More information